{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:22:43Z","timestamp":1789179763173,"version":"build-2803163510"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,3,12]]},"DOI":"10.1001\/jama.2024.0801","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T15:01:11Z","timestamp":1710255671000},"page":"834","source":"Crossref","is-referenced-by-count":5,"title":["The Public Health Challenge of \u0394<sup>8<\/sup>-THC and Derived Psychoactive Cannabis Products"],"prefix":"10.1001","volume":"331","author":[{"given":"Jennifer M.","family":"Whitehill","sequence":"first","affiliation":[{"name":"Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"jed240006r1","article-title":"Adolescent ?8-THC and marijuana use in the US.","author":"Harlow","journal-title":"JAMA"},{"issue":"11","key":"jed240006r3","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2105\/AJPH.2021.306499","article-title":"The hemp loophole: a need to clarify the legality of delta-8-THC and other hemp-derived tetrahydrocannabinol compounds.","volume":"111","author":"Leas","year":"2021","journal-title":"Am J Public Health"},{"issue":"12","key":"jed240006r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.47373","article-title":"Past-year use prevalence of cannabidiol, cannabigerol, cannabinol, and d8-tetrahydrocannabinol among US adults.","volume":"6","author":"Wilson-Poe","year":"2023","journal-title":"JAMA Netw Open"},{"key":"jed240006r5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DHPS.S391857","article-title":"Delta-8, a cannabis-derived tetrahydrocannabinol isomer: evaluating case report data in the Food and Drug Administration Adverse Event Reporting System (FAERS) database.","volume":"15","author":"Simon","year":"2023","journal-title":"Drug Healthc Patient Saf"},{"issue":"6","key":"jed240006r6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/add.v118.6","article-title":"Delta-8 tetrahydrocannabinol: a scoping review and commentary.","volume":"118","author":"LoParco","year":"2023","journal-title":"Addiction"},{"issue":"15","key":"jed240006r7","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1111\/bph.v179.15","article-title":"Review of delta-8-tetrahydrocannabinol (?8 -THC): comparative pharmacology with ?9 -THC.","volume":"179","author":"Tagen","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"jed240006r8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1037\/pha0000565","article-title":"A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.","volume":"31","author":"Bergeria","year":"2023","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"jed240006r9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/can.2021.0124","article-title":"Consumer experiences with delta-8-THC: medical use, pharmaceutical substitution, and comparisons with delta-9-THC.","volume":"8","author":"Kruger","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"jed240006r10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.15288\/jsad.23-00008","article-title":"Delta-8, delta-10, HHC, THC-O, THCP, and THCV: what should we call these products?","volume":"84","author":"Rossheim","year":"2023","journal-title":"J Stud Alcohol Drugs"},{"issue":"1","key":"jed240006r11","first-page":"100","article-title":"Cannabis retailer communication about cannabis products, health benefits, and risks: a mystery shopper study of licensed retailers in five U.S. cities.","volume":"85","author":"Romm","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"issue":"1","key":"jed240006r12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jadohealth.2023.01.020","article-title":"Absence of age verification for online purchases of cannabidiol and delta-8: implications for youth access.","volume":"73","author":"Egan","year":"2023","journal-title":"J Adolesc Health"},{"issue":"1","key":"jed240006r13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13181-023-00974-y","article-title":"Commercial delta-8 THC products: an analysis of content and labeling.","volume":"20","author":"Kaczor","year":"2024","journal-title":"J Med Toxicol"},{"issue":"1","key":"jed240006r14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1021\/acs.chemrestox.1c00388","article-title":"Novel ?8-tetrahydrocannabinol vaporizers contain unlabeled adulterants, unintended byproducts of chemical synthesis, and heavy metals.","volume":"35","author":"Meehan-Atrash","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"jed240006r15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42238-023-00191-y","article-title":"Self-reported adverse events associated with ?8-tetrahydrocannabinol (Delta-8-THC) Use.","volume":"5","author":"Leas","year":"2023","journal-title":"J Cannabis Res"},{"issue":"2","key":"jed240006r16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s13181-022-00927-x","article-title":"Delta-8-tetrahydrocannabinol exposure and confirmation in four pediatric patients.","volume":"19","author":"Shaker","year":"2023","journal-title":"J Med Toxicol"},{"key":"jed240006r2","unstructured":"Centers for Disease Control and Prevention. Increases in availability of cannabis products containing delta-8 THC and reported cases of adverse events. September 14, 2021. Accessed February 15, 2024. https:\/\/stacks.cdc.gov\/view\/cdc\/109759"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2816109\/jama_whitehill_2024_ed_240006_1709580706.0325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T15:01:16Z","timestamp":1710255676000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2816109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.0801","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}